The expression of CD38 by B cells of chronic lymphocytic leukemia (B-CLL) was studied in 20 untreated patients. The cells expressed abundant CD38 (relative fluorescence intensity range, 6 to 15) in 6 cases (group I patients), whereas CD38 expression was low to absent (relative fluorescence intensity range, 0 to 3) in the remaining cases (group II patients). Exposure of the cells from group l patients to goat antihuman p chain antibodies (Gap-ab) resulted in the elevation of intracellular free Ca2+ concentration ([Ca2'li) followed by apoptosis. In contrast, exposure of group II cells to Gapab was not followed by increased levels of [Ca2'li, programmed cell death or cell proliferation. No differences in the expression of surface IgM were noted in the two groups of B-CLL cells. Normal peripheral blood B cells, which expressed low to absent CD38, were capable of mobilizing -CELL CHRONIC lymphocytic leukemia (B-CLL) is caused by the monoclonal expansion of B lymphocytes.' The large majority of the neoplastic cells appear to be blocked at a relatively mature stage of differentiation, in which the cells express surface Ig (SIP).* Considerable debate has been raised regarding the mechanisms underlying the accumulation of monoclonal cells. The current views consider an array of possibilities that include defective transducing pathways of the stimulatory signals delivered through SI^' .^ or altered responsiveness to signals provided by the cellular envir~nrnent.~.' These defects may contribute to the accumulation of lymphocytes either by favoring the expansion of cells in the absence of differentiation into plasma cells or by preventing their physiologic apoptotic mechanisms. In recent years, an increasing body of evidence has indicated that disparate defects of both apoptosis and activation may exist in the various B-CLL case^.^"^ However, the identification of phenotypic markers recognizing the various cases with different physiologic features has been diffiCUlt.4J3
The expression of CD38 by B cells of chronic lymphocytic leukemia (B-CLL) was studied in 20 untreated patients. The cells expressed abundant CD38 (relative fluorescence intensity range, 6 to 15) in 6 cases (group I patients), whereas CD38 expression was low to absent (relative fluorescence intensity range, 0 to 3) in the remaining cases (group II patients). Exposure of the cells from group l patients to goat antihuman p chain antibodies (Gap-ab) resulted in the elevation of intracellular free Ca2+ concentration ([Ca2'li) followed by apoptosis. In contrast, exposure of group II cells to Gapab was not followed by increased levels of [Ca2'li, programmed cell death or cell proliferation. No differences in the expression of surface IgM were noted in the two groups of B-CLL cells. Normal peripheral blood B cells, which expressed low to absent CD38, were capable of mobilizing -CELL CHRONIC lymphocytic leukemia (B-CLL) is caused by the monoclonal expansion of B lymphocytes. ' The large majority of the neoplastic cells appear to be blocked at a relatively mature stage of differentiation, in which the cells express surface Ig (SIP).* Considerable debate has been raised regarding the mechanisms underlying the accumulation of monoclonal cells. The current views consider an array of possibilities that include defective transducing pathways of the stimulatory signals delivered through SI^' .^ or altered responsiveness to signals provided by the cellular envir~nrnent.~.' These defects may contribute to the accumulation of lymphocytes either by favoring the expansion of cells in the absence of differentiation into plasma cells or by preventing their physiologic apoptotic mechanisms. In recent years, an increasing body of evidence has indicated that disparate defects of both apoptosis and activation may exist in the various B-CLL case^.^"^ However, the identification of phenotypic markers recognizing the various cases with different physiologic features has been diffiCUlt. 4J3 In the present study, we used anti-CD38 monoclonal antibodies (MoAbs) to analyze the cells from B-CLL patients by immunofluorescence. Indeed, we found that this marker distinguishes between two groups of patients whose neoplastic cells display different features. Thus, in the patients whose cells expressed abundant CD38, cell stimulation by anti-Ig reagents could be observed in vitro. Such stimulation invariably caused cell apoptosis. In contrast, the cell populations that failed to express CD38 were refractory to in vitro stimulation and failed to undergo apoptosis under identical conditions.
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MATERIALS AND METHODS
Cell preparation. Twenty patients with B-CLL at 0, I, or I1 stages of the Rai classification were studied at diagnosis and before treatment. B cells were purified from peripheral blood (PB) mononuclear cells (MNC) of the patients by removing T cells by the resetting method with sheep erythrocytes and monocytes by adherence to plastic surfaces, as previously reported.I4 Flow cytometry analysis (see below) showed that the purified B-CLL cells were composed of more than 95% of CD19+ and CD5' cells and less than 3% of [Ca2'11 and of proliferating after exposure to Gap-ab. The collected data suggest that, although group I B-CLL cells were able to transduce the signals delivered by IgM crosslinking, this pathway was severely impaired in group II B-CLL cells. However, unlike that observed in normal circulating B cells, stimulation of group I cells with Gap-ab resulted in apoptosis rather than proliferation. CD38 did not appear to be directly involved in [Ca2+li mobilization induced by Gapab in group I B-CLL cells because their exposure to anti-CD38 monoclonal antibodies failed to cause [Ca2'li mobilization or to block the [Ca2+li response induced by Gap-ab. These data indicate that CD38 expression identifies a particular subset of B-CLL cells with defined functional properties, including the propensity to undergo apoptosis. 0 1996 by The American Society of Hematology.
CD3+ T cells and CD68' monocytes. PB B cells from normal donors were obtained from MNC by removing T cells and monocytes as detailed above. These B-cell preparations contained more than 80% B cells as determined by immunofluorescence using anti-CD19 MoAb. The remaining cells were composed of monocytes (15% to 18% CDllb' cells) and T cells (0% to 3% CD3+ cells). Selected experiments were performed on EBV' Burkitt's lymphoma (BL) cell line (LAM), originated as previously reported."
ImmunoJZuorescence. The murine MoAbs used in this study were anti-CD19 (leu 19), anti-CD5, anti-CD3, anti-IgM, anti-CD1 lb from Becton Dickinson (Palo Alto, CA); anti-CD21, anti-CD23, anti-IgD, and anti-CD68 from Dakopatt (Glostrup, Denmark); anti-CD20 from Coulter (Hialeah, FL); anti-CD40 donated by Dr S.M. (1 mg/mL) and CaClz ( 1 mmol/L) for 30 minutes at 37°C. Cells were then washed three times, resuspended in 2 mL of the same buffer, and exposed to the appropriate stimuli (see below). [Ca"], was detected by excitation of the probe at two alternative wavelengths (340 and 380 nm) and by measuring the emitted fluorescence at 510 nm with a spectrofluorometer (Perkin-Elmer Cetus, Norwalk, CT). A separate calibration for each sample was performed. When indicated, the cells were exposed to stimuli in the presence of 1 mmol/L EDTA (Sigma Chemical CO, Milan, Italy). Stimuli added during the test were polyclonal goat antihuman Ig p chain antibodies (Gap-ab) or normal goat globulins (NGG), both used at the concentrations from 10 ng/ mL to 100 pg/mL (both from Southern Biotechnology Associates), a rabbit F(ab'I2 antihuman IgM (Accu-specs, Westbury, NY; range of concentrations used from I O ng/mL to 100 pg/mL), a murine monoclonal antihuman Ig p chain antibody (anti-p MoAb; S pgl mL; Becton Dickinson) followed by a goat antimouse Ig antiserum (GAM-Ig; Southern Biotechnology). anti-CD39 MoAb (S pg/mL) followed by GAM-Ig, and one of the three different anti-CD38 MoAb described above (1 pg/mL) followed by GAM-Ig. The concentrations of the MoAb were selected based on the results of preliminary titration experiments.
Apoptosis. Cells ( I X IOh/mL) were cultured in RPM1 1640 medium supplemented with 10% fetal calf serum (FCS; both from GIBCO, Paisley, UK) for various time intervals. The cells were exposed to the following stimuli in various combinations: Gap-ab, rabbit F(ab')> antihuman IgM, and NGG (all used from 10 ng/mL to 100 pg/mL): one of the three different antiLCD38 MoAb (184) described above (S pg/mL); anti-CD40 MoAb (ascites used at the dilution of 1:500), recombinant interleukin-4 (rIL-4; 100 U/mL; Genzyme Corp, Boston, MA). The optimal concentrations of the stimuli used were selected after titration experiments.
At the end of culture, the cells were recovered, and apoptosis was measured by three different methods. First, permeabilized cells were stained with propidium iodide (PI; SO pg/mL; Sigma Chemical CO) and the amount of DNA fragmentation was calculated by flow cytometer analysis, as previously described." The results were expressed as the percentage ratio between fragmented and total DNA. Second, Giemsa-stained cytospin preparations were analyzed by light microscopy and the percentage of cells with morphologic features of apoptosis was calculated out of the total number of 200 cells. Third, DNA laddering in purified low molecular weight DNA was measured according to the method of Facchinetti et al." Briefly, 10' cells were resuspended in S mL of ice-cold lysing buffer (IS0 mmol/L NaCI, SO mmol/L Tris [pH 7.61, 1 % Triton XIOO, 10 mmol/L EDTA) containing I O pg DNase-free RNase (Boehringer Manheim Biochemicals, Indianapolis, IN); after 10 minutes on ice, the sample was centrifuged for S minutes at 2,000 rpm, and the supernatant containing DNA fragments was recovered. After phenol extraction and ethanol precipitation, the samples were resuspended in S0 pL TE (Tris-EDTA). After S minutes at 60°C, the fragments were loaded on a 1.5% agarose gel and run at 7.5 V/cm for 3 hours. DNA laddering was detected by staining with ethidium bromide.
Cell proliferarion. Cells were cultured as described above. At the end of culture, cell proliferation was measured by PI \taining of the cells and analysis of cell cycle phases by flow cytofluorimetry. The percentage of the cells present in each cell cycle phase WBS calculated by cellfit program." Alternatively, 5-Bromo-deoxyuridine (BrdUrd) incorporation in DNA was measured by flow cytometry." Briefly, cells were pulsed with BrdUrd (Sigma) during the laat 20 minutes of the culture. Subsequently, cells were stained with antiBrdUrd MoAb (BioCell Consulting, Grellingen. Switzerland) and FITC-conjugated GAM Ig, followed by incubation with P1 ( I pg/ mL). Two-color fluorescences (FLI, BrdUrd incorporation; FL2, DNA content) were analyzed on FACScan.
RESULTS
CD38 expression distinguishes two groups of B-CLL cells with different [Cu2+]
, response to IgM cross-linking. The expression of CD38 by the malignant cells of 20 B-CLL patients was investigated by flow cytometry. CD38 was expressed at high density in 6 cases, whereas, in the remaining cases, CD38 was absent (10 cases) or expressed at low levels (4 cases). These results were confirmed by observations with three different anti-CD38 MoAbs. The patients were divided into two groups: the first, group I, included patients with leukemic cells with high CD38 expression; and the other, group 11, was composed of cases with low to absent levels of CD38 (Fig 1A) . Further analysis failed to disclose differences in surface marker expression between the malignant cells from group I and group I1 patients. In all cases, more than 95% of the malignant cells expressed CD19, CD20. CD21, CD23, CD39, CD40, and CD5. Although variations existed among the different cases, sIgM and sIgD were generally expressed in low quantities. All the B-CLL cases expressed Ig-associated protein p chain (CD79b; Fig IB) .
The cells from 5 patients (A, B, C, D, and E) of group I and from 5 patients of group I1 (F and G with low CD38 expression and H, I, and L with absent CD38 expression) were exposed to Gap-ab (10 pg/mL) and studied for [Ca"], mobilization. The RFI of sIgM stainings did not differ significantly in the two groups (RFI ranges were 3 to 20 and 4 to 24, respectively). In the B-CLL cells from group I, G a pab induced a [Ca"], increase that reached a peak in approximately 60 to 80 seconds. The [Ca"Ii level then declined for the next 8 minutes, although it remained higher than the basal level. In the cells from group 11, the level of [Ca"], was unchanged or only marginally increased on exposure to Gap-ab compared with control cells exposed to NGG. [C,'+], mobilization was not observed over a wide range of Gapab concentration (from 10 ng/mL to 100 pg/mL) and not even when the measurements were extended for up I S minutes (data not shown). Representative profiles of [Ca"], mobilization ( 1 from each group of patients) are reported in Fig   2A . Figure 2A also shows the mean values -+ SD determined in all of the patients studied.
In another set of experiments, the cells from the group I or group I1 cases studied above were exposed to a rabbit F(ab')? antibody against human IgM (10 pg/mL; Fig 2B) . Admittedly. these possibilities were somewhat remote because of the poor binding of goat IgG to human Fc receptors.:"
Next. B-CLL cells were exposed to anti-p MoAb (5 pg/ mL). This treatment induced a slight [Ca"Ii increase only in group I B-CLL cells that increased substantially when the anti-p MoAb was cross-linked with GAM-Ig (Fig 2C) . The values of [Ca"Ii mobilization observed with these reagents were similar to those induced by Gap-ab. No [Ca"]! mobilization could be seen in group I1 cells (Fig 2C) . When the cells were exposed to another MoAb (anti-CD39 MoAb) in place of anti-p MoAb, no [Ca"], mobilization was observed in any of the cell samples tested. even when GAM-Ig was subsequently added to cross-link anti-CD39 MoAb on the cell surface (Fig 2C) .
The exposure of group I B-CLL cells to Gap-ab in the presence of EDTA resulted in a [Ca"], increase that was only marginally lower that the one observed in the absence of EDTA. This indicates that the increase in [Ca"li was caused by the release of the ions from intracellular stores (data not shown).
Failure of CD38 MoAb to irrclrrcc [Ca2+]i n~obili~crtior~. Next, we investigated whether exposure of cells from group I B-CLL patients to anti-CD38 MoAb could result in [Cd-li mobilization. Three different anti-CD38 MoAbs failed to induce mobilization in the cells from the S group I B-CLL patients (Fig 3A) . Furthermore, [Ca"li mobilization was not observed when the anti-CD38 MoAb bound to the cell surface was cross-linked with GAM-Ig (data not shown). Under the same test conditions, Gap-ab induced an increase in [Ca"li ( Fig 3A) .
Group I B-CLL cells were exposed to anti-CD38 MoAb (IB4) for the times indicated in Fig 3B and stimulated with Gap-ab. An early and rapid increase of [Ca"li was observed after exposure to Gap-ab, irrespective of whether the cells were pretreated with anti-CD38 MoAb or an unrelated MoAb (anti-CD39 MoAb). Cross-linking of anti-CD38 (or of control anti-CD39) MoAb with GAM-Ig did not alter the results. These findings indicate that anti-CD38 MoAb did not block or synergize with the [Ca'+Ii mobilization induced by Gap-ab.
Cop-oh induces opoptosis irt group I B-CLL cells. Apoptosis is often dependent on a sustained cytosolic calcium increase."'.'' Therefore. it was of interest to investigate whether the [Ca"Ii mobilization caused by exposure to Gapab also resulted in programmed cell death. Purified B-CLL cells were cultured with Gap-ab ( I O pg/mL) for 24 hours and evaluated for apoptosis by PI staining and flow cytometry. When B-CLL cells were cultured in medium alone (data not shown) or in the presence of NGG. low or absent DNA fragmentation was observed in all of the sample tested ( Fig  4A) . Exposure to Gap-ab resulted in a substantial amount of apoptosis in group I B-CLL cells. whereas apoptosis was low (case L; Fig 4A) or absent (cases F. G, H, and I: Fig  4A) in group I1 B-CLL cells.
The occurrence of apoptosis in Gap-ab-stimulated cells from group I B-CLL was confirmed by morphologic studies on Giemsa-stained cytospin preparations (Fig 4B) . Condensed and fragmented nuclei were present in group I B-CLL cells. but not in group I1 B-CLL cells treated in the same manner. Gel electrophoresis disclosed DNA laddering typical of apoptosis in group I B-CLL cells cultured with Gap-ab for 24 hours (Fig 4C) . DNA fragmentation was barely visible when the same B-CLL cells were cultured in medium alone (Fig 4C) . Virtually no DNA fragmentation was detected in group II B-CLL cells irrespective of whether they were exposed to Gap-ab (Fig 4C) . In this regard. it is of interest that apoptosis of group 11 B-CLL cells was not observed with a wide range of doses of Gap-ab (from 10 ng/mL to 100 pg/mL). Moreover, exposure to a rabbit F(ab'), antihuman IgM either in free solution (from 10 ng/mL to 100 pg/mL) or immobilized onto plastic plates failed to induce apoptosis of group I1 B-CLL cells (data not shown).
The cells from three B-CLL cases from each group were exposed to Gap-ab or NGG for different times and DNA fragmentation was examined by PI staining. Gap-ab induced 45% ? 15% apoptosis of group I B-CLL cells by 18 to 24 hours. The values observed remained constant for the following period (Fig 5 ) . In the cultures that contained NGG, there was also cell death by apoptosis. However. this was substantially inferior to that observed in the cultures exposed to Gap-ab. In group I1 B-CLL cells, there was a small DNA fragmentation during the first 72 hours, irrespective of whether the cells were exposed to Gay-ab or NGG. This fragmentation increased, albeit marginally, in the late culture times both in the presence and in the absence of the stimulus (Fig   5 ) . Notably, spontaneous apoptosis was consistently greater in group I than in group I and group I1 patients consistently remained in the GO-I1 B-CLL cells.
G1 phase of the cell cycle after Gap-ab stimulation. A Gap-ab-induced upprosis occurs in cells at the GOsubstantial proportion of cells in S phase of cell cycle G1 phase ofthe cell cycle. Cells from group I and group could be observed in control LAM BL cell line studied I1 patients were exposed to Gap-ab (10 pg/mL) for differwith the same method. ent times, stained with PI, and analyzed for the cell cycle Cells from group I and group I1 patients were analyzed by flow cytometry. As shown in Fig 6A, Fig 4A) . The data represent the mean k SD of the values obtained. Fig 6B, the cells that incorporated BrdUrd and entered in the S-GJM phases was observed in control LAM BL cell the S phase of the cell cycle, upon exposure to Gap-ab, were line (Fig 6B. box 3) . Notably, apoptosis was evident in the negligible or virtually absent in both group I and group I1 group I and not in the group I1 cells exposed to Gap-ab ( Fig  B-CLL (Fig 6B, box 3) . Again, BrUrd incorporation together 6B, box 1). although the values recorded were somewhat with a substantial proportion of cells that progressed through lower than those obtained in the experiments reported in Fig   Fig 6. Cell cycle analysis and BrdUrd labeling of group I and group II B-CLL cells exposed t o Gap-ab. 4A due to the different sensitivity of the methods used. The cells undergoing apoptosis did not incorporate BrdUrd, as shown by the absence of BrdUrd stained cells in the unmarked box below box 3 (in Fig 6B) . This is consistent with the concept that group I B-CLL cells underwent apoptosis without entering into the cell cycle.
rIL-4 but not anti-CD38 MoAh protects group I R-CLL cells from apoptosis. Previously, it was shown that anti-CD38 MoAb (IB4) could inhibit the spontaneous apoptosis of normal germinal center (GC) B cells in vitro." Therefore, it was of interest to determine whether anti-CD38 MoAb could inhibit apoptosis of group I B-CLL cells. Three different samples of group I B-CLL cells were incubated with Gap-ab ( I O pg/mL) in the presence or in the absence of an anti-CD38 MoAb (IB4; 1 pg/mL). The cells were also exposed to Gap-ab and rIL-4 or anti-CD40 MoAb, which are known to prevent B-cell apoptosis in various experimental
The cells were cultured for 36 hours and examined for DNA fragmentation by PI staining. As shown in Fig 7, anti-CD38 MoAb did not prevent Gap-ab-induced apoptosis, even when its concentration was increased 10-fold (data not shown). rIL-4 substantially reduced the G a p ab-induced apoptosis, whereas anti-CD40 MoAb failed to prevent apoptosis.
Normal peripheral blood B cells express low levels qf CD38 and do not undergo apoptosis upon exposure to Gapah. Next, we investigated the expression of CD38 by normal PB B cells. These PB B cells expressed low levels of CD38, thus resembling group I1 B-CLL cells (Fig 8A) . They also expressed the same markers as both group I and group I1 B-CLL cells. CD5 was detected on some but not all of the cells. When PB B cells were exposed to anti-p MoAb. a significant [Ca"Ii mobilization was observed and was substantially increased by the addition of GAM-Ig (Fig 8B) .
The same values of [Ca'+Ii mobilization were observed when PB B cells were stimulated with Gap-ab (data not shown). Moreover, exposure to Gap-ab for 18 hours failed to induce apoptosis of PB B cells ( Fig 8C) ; instead, the cells were induced into the cell cycle, as shown by the appropriate studies on cells that were incubated with Gap-ab for 18. 36, and 48 hours. Figure 8D shows a typical experiment performed on PB B cells incubated with Gap-ab for I8 hours.
DISCUSSION
The present study identified two discrete groups of B-CLL cells. The first group (group I) expressed CD38, was apoptosis-prone. and was characterized by a rapid [Ca'"], mobilization after cross-linking of slg. The second group (group 11) included cells expressing low to nil CD38 that failed to respond to stimulation with anti-IgM antibodies and were apoptosis-resistant. These observations raise a number of issues regarding the role of CD38 in B-cell activation, calcium mobilization, and apoptosis. In addition, they might provide new tools for the possible subclassification of B-CLL cells.
The present study shows a correlation between the process of apoptosis and CD38 expression by B-CLL cells. CD38+, but not CD38-B-CLL cells underwent apoptosis upon exposure to Gap-ab. Moreover, spontaneous apoptosis was observed in a substantial proportion of group I cells when kept in culture without stimuli (Fig 5) . In these conditions, group 11 cells displayed little. if any, apoptosis. Finally, Gap-ab failed to induce apoptosis of normal B cells that expressed low levels of CD38. Previous studies showed that B cells that are prone to apoptosis express CD38. Thus, the cells of certain Burkitt's lymphoma cell lines express abundant CD38 and undergo apoptosis in vitro after the removal of FCS from the culture media or exposure to Gap-ab. In contrast, the cells from Burkitt's lymphoma cell lines that do not express CD38 are resistant to apoptosis.3". '' Moreover, when transfected with c-myc carrying vectors in vitro, B cells of normal lymphoblastoid cell lines that are normally apoptosis-resistant acquire both the propensity to apoptosis and expression of CD38.23 Finally, GC B cells that undergo apoptosis spontaneously in vitro express abundant surface cess of apoptosis remains to be established.
Expression of CD38 and the propensity to apoptosis suggest similarities between GC B cells and group I B-CLL cells. Because of this, it is tempting to speculate that group I B-CLL cells are in the process of differentiating into GC B cells and thus represent a more mature stage of B cells than group I1 B-CLL cells. This hypothesis would also be supported by the observation that normal B cells, whereas maturing into GC B cells acquire the capacity to express CD38." However, there are several differences between GC B cells and group I B-CLL cells. For example, apoptosis of group I B-CLL cells was prevented by rIL-4 and not by exposure to anti-CD40 or CD38 MoAb. Instead, these reagents were found to be very efficient at inhibiting apoptosis of GC B cells.2',2x Finally, GC B cells are actively cycling cells and may conceivably enter the apoptotic pathway after the committment point in late GIzX; in group I B-CLL cells, programmed cell death occurs before this stage (Fig 6B) . Apoptosis can be initiated at several phases of the cell cysuggest that group I B-CLL may be committed to entering the GC B-cell differentiation pathway, but may have lesions CD38.31.32 Whether CD38 has a physiologic role in the procle.3J.?5 Taken together, the considerations mentioned above anti-CD38 MoAb did not appear to enhance or block the stimulating signals delivered through surface Ig. Third, anti-CD38 MoAb did not induce apoptosis of B-CLL cells. Finally, anti-p MoAbs were found to be capable of stimulating normal recirculating B cells that expressed low to absent levels of CD38. These observations were somewhat surprising, especially in light of previous data concerning the CD38 molecule.77 In humans, anti-CD38 MoAbs prevent spontaneous apoptosis of GC B cells" and block lymphopoiesis," although they do not appear to be capable of inducing proliferation of normal B cells or enhancing the proliferation promoted by exposure to Gap-ab (our unpublished data). However, in the mouse, agonistic anti-CD38 MoAbs induce [Ca"li mobilization in B cells and stimulate their proliferaactivity and to regulate the synthesis of cADP ribose?'"3 which in turn upregulates the ryanodine receptor-mediated [Ca"li mobilization.u~'5 Based on these observations, it has been suggested that CD38 may participate in cell activation through this particular pathway.'" At present, it is difficult to provide explanations for the different effects of anti-CD38 MoAb on the various human B-cell subsets. Moreover. the situation becomes even more complicated when the data in humans and mice are compared, although several different hypotheses have been proposed.'" tion..' ".?" CD38 was shown to have a bifunctional enzymatic The inability of group 11 B-CLL cells to mobilize [Ca"Ii upon cross-linking of surface IgM raises the possibility that their signal transduction pathway is blocked. This block does not appear to be related to faulty expression of signal transducing molecules associated to Ig such as CD19, CD20, CD21. and CD79b (Fig I B) .J7 Nevertheless, it may involve the early steps of the signal transducing pathways because neither [Ca'"], mobilization nor tyrosine phosphorylation (data not shown) induced by exposure to Gap-ab seems to be operative. Blocks at various levels of the signal transducing pathway have previously been reported in B-CLL although it is not clear whether they represent specific lesions of the leukemic cells or a physiologic feature of normal cells at the same maturation stage as B-CLL cells. In connection with this. it is of note that several studies in experimental animals have documented blocks in the signal transduction pathway of normal B cells at relatively early maturational stages.'x.J4
A final issue to be discussed is the relationship between group I and group 11 B-CLL. They may be two subtypes of B-CLL or represent different maturation stages of B-CLL cells that can convert from one type into the other. Support to the latter hypothesis is provided by some preliminary observations. For example, when CD38 expression by 20 untreated B-CLL patients was compared with that of 20 patients under treatment with steroids and alkylating agents, it was found that. although the proportion of cases expressing CD38 in the untreated group was similar to that observed in this study (r30%), none of the treated cases expressed CD38. Moreover, a longitudinal study in 1 patient with high CD38 expression before and after therapy with chlorambucil and steroids recorded a decrease in CD38 expression after the beginning of therapy. Finally, we have recently observed Previous studies showed that B-CLL cases can be subdivided into subgroups depending on the capacity of the malignant cells to express CD1 lb.4,50 Although we have confirmed such heterogeneity for CD1 l b expression, no correlation was found with that of CD38 in the single cases. Similar studies are currently in progress for CD1 lc50,51 and APO-1 (CD95) expression.' '
The identification of different subsets of B-CLL characterized by different phenotypic and functional features may offer new possibilities in the clinical approach to the disease, leading to more specialized treatment of patients with different clinical courses and/or response to therapy. If therapy eliminates preferentially group I cells (thus converting group I cases into group I1 cases), then the question arises of whether this conversion may represent a progression step into a more aggressive form of the disease. Apoptosis induced by physiologic signals or even by chemotherapeutical treatments may be poorly operative or not operative in group I1 cells, thus facilitating the survival of the malignant clone.
